Open access
Jul 2026
Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 2260043
Results demonstrate that AZD6563, at reduced doses, matches the cellular immunogenicity of BNT162b2 while enhancing B cell cross-reactivity and TCR diversity in older adults, supporting its potential as a next-generation COVID-19 vaccine candidate.
Michael D. Powell, Nicholas G. Battaglia, Lee-Jah Chang et al.
· Journal of Immunology · 0 citations